SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following news of a partnership with Verizon to bring satellite-to-phone service by 2026, driving excitement among investors. The community is actively discussing the potential impact of this deal, particularly the lack of specific financial commitments in the announcement, alongside speculation about further catalysts like the "golden dome" project. Despite a recent ATM offering, the stock's positive price action suggests strong confidence in ASTS's long-term prospects within the burgeoning space-based cellular service sector.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending downwards as shareholders discuss the potential impact of an upcoming share lock-up expiration, leading to concerns about possible insider selling and dilution. The community is debating entry points and whether the current price drop is an overreaction or a sign of further declines, with some viewing it as a buying opportunity while others express concern about the stock's future. Discussions also mention comparisons to similar situations with other stocks and speculation about potential manipulation.

Universe Pharmaceuticals, Inc. is a pharmaceutical company. The firm is focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. It also sells biomedical drugs, medical instruments, traditional Chinese medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. The company was founded on March 2, 1998 and is headquartered in Ji'an, China.

Universe Pharmaceuticals INC

UPC is trending due to discussions around its low float and substantial cash reserves, fueling speculation about potential buybacks or strategic moves. The community is closely watching for news, particularly related to potential cryptocurrency ventures, that could trigger a significant price increase. Some traders are drawing comparisons to recent low-float bio stock runners and anticipating a similar breakout for UPC.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending due to a recently announced $75 million investment to scale its AI connectivity solutions, prompting community speculation about the strategic investor. Discussions revolve around the potential impact on POET's position in the AI hardware landscape, especially concerning chip-to-chip communication and possible M&A activities. Community members are also focused on the company's existing partnerships and its capacity to address bottlenecks in AI data centers.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending as it reaches new 52-week highs, fueled by a new multi-launch agreement and overall bullish sentiment. The community is actively discussing upcoming catalysts like the Neutron launch and potential government contracts, contributing to the stock's momentum. Despite some profit-taking and analyst concerns about valuation, many investors remain optimistic about Rocket Lab's long-term growth potential in the expanding space economy.

AlphaTON Capital Corp. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. Its portfolio includes first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. The company was founded by Gregory H. Bailey and James Mellon in 1973 and is headquartered in Road Town, British Virgin Islands.

AlphaTON Capital Corp.

AlphaTON Capital ($ATON) is trending due to news of a closed financing round and the acquisition of TON tokens, sparking discussions about its strategic focus on Telegram's blockchain ecosystem. Community members are actively debating the potential for significant price movement and short squeezes, while others are wary of potential pump-and-dump schemes. The stock's low float and connection to the crypto space are also contributing to the heightened interest.

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

TransCode Therapeutics Inc

TransCode Therapeutics (RNAZ) is trending due to positive Phase 1a trial results for its metastatic cancer drug TTX-MC138, highlighting stable disease in some patients and no dose-limiting toxicities. The community is actively discussing the potential for a short squeeze, fueled by the low float and upcoming shareholder meeting, while also weighing the possibility of a reverse stock split. Some investors are optimistic about a potential partnership or buyout given the promising clinical data, drawing comparisons to other successful biotech companies in the sector.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as the deep-sea mining sector gains traction, with community members discussing potential short squeezes and a possible breakout. Optimism is fueled by anticipation of government partnerships and regulatory approvals, particularly the NOAA decision. Bullish investors are focused on the company's long-term potential in the critical minerals market.

Fitell Corp. engages in the business of selling gym and fitness equipment. It also offers turnkey solution for personal training studios and commercial gym chains. Its brands include Muscle Motion, Rapid Motion, and FleetX. The company was founded in 2007 and is headquartered in Sydney, Australia.

Fitell Corp - Ordinary Shares - Class A

Fitell Corp

FTEL is trending as traders discuss its potential for a significant run, citing its small float and recent news regarding a Solana treasury initiative. Community members are actively watching for volume increases, which they believe could trigger a parabolic move similar to other low-float stocks. Some traders are pointing to a potential target around the $10-$20 range, drawing parallels to recent runners in the market.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending due to renewed investor optimism and speculation surrounding upcoming data presentations and potential positive catalysts. Community members are actively discussing the possibility of a short squeeze and a rise toward significantly higher price targets. Recent price action suggests growing confidence in Sarepta's pipeline and long-term potential despite past setbacks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech stocks jump as Makary outlines FDA vision, RBC comments

Investing.com -- Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers. In his first major interview since taking office, Makary emphasized pragmatic reforms, faster drug approvals, and modernized use of real-world data across the agency.

Design Therapeutics, Inc. (NASDAQ:DSGN) Director Purchases $66,605.66 in Stock

Design Therapeutics, Inc. (NASDAQ:DSGN  Get Free Report) Director John P. Schmid purchased 17,809 shares of Design Therapeutics stock in a transaction dated Monday, March 25th. The shares were...

Design Therapeutics (DSGN, $3.9) RSI Indicator left the overbought zone on March 27, 2024

This is a signal that DSGN's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Design Therapeutics (DSGN, $3.58) RSI Indicator left the overbought zone on March 26, 2024

Equities Analysts Set Expectations for Design Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:DSGN)

Design Therapeutics, Inc. (NASDAQ:DSGN  Free Report)  Analysts at Leerink Partnrs boosted their Q1 2024 EPS estimates for shares of Design Therapeutics in a research report issued on...

Design Therapeutics (DSGN, $3.25) RSI Indicator left the overbought zone on March 21, 2024

Design Therapeutics, Inc. (NASDAQ:DSGN) Receives Consensus Rating of "Hold" from Brokerages

Design Therapeutics, Inc. (NASDAQ:DSGN  Get Free Report) has been given a consensus recommendation of Hold by the seven research firms that are currently covering the company...

Design Therapeutics (NASDAQ:DSGN) Receives "Neutral" Rating from Wedbush

Design Therapeutics (NASDAQ:DSGN  Get Free Report)s stock had its neutral rating reissued by Wedbush in a report issued on Wednesday, Benzinga reports. They presently have...

Design Therapeutics Inc (DSGN) Reports Full Year 2023 Financial Results and Pipeline Progress

Advancements in GeneTAC Platform and Strong Cash Position HighlightedRelated Stocks: DSGN...

Design Therapeutics reports Q4 EPS (21c), consensus (31c)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded by Pratik Shah and Aseem Z. Ansari on December 18, 2017 and is headquartered in Carlsbad, CA.

Design Therapeutics Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$6.49
Prev Close	$6.35
Open	$6.43
Dividend Yield	0.00%
50-Day Moving Average	$5.55
Beta	1.49
Avg. Volume	189,279.90
PE Ratio	-5.80

52-Week High	$7.77
52-Week Low	$2.60
Market Capitalization	$369.59M
EPS (Annual)	-$0.8763
Price to Book	1.73
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

DSGN Design Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DSGN News